Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 07:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201...
November 08, 2025 11:25 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses ...
November 04, 2025 17:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second...
October 09, 2025 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
October 02, 2025 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
September 18, 2025 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
September 02, 2025 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
August 31, 2025 10:15 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for...
August 08, 2025 08:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
August 06, 2025 16:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1...